摘要
目的探讨miR-203靶向抑制Survivin对卵巢癌SKOV3及OVCAR3细胞增殖、迁移及侵袭的影响。方法构建过表达miR-203、Survivin及空白对照组的慢病毒载体,转染卵巢癌SKOV3和OVCAR3细胞,嘌呤霉素筛选后构建空白对照组、过表达miR-203组、过表达Survivin组及过表达miR-203联合Survivin组卵巢癌细胞系。Western blotting方法测定各组卵巢癌细胞中Survivin及上皮-间质转化(EMT)相关蛋白的表达;MTT和平板克隆实验检测卵巢癌细胞增殖能力的改变;Transwell实验检测对细胞迁移和侵袭能力的影响。结果(1)过表达miR-203抑制Survivin的表达及EMT(P<0.05);(2)MTT、平板克隆实验及transwell实验显示,与空白对照组相比,过表达miR-203组能够抑制卵巢癌细胞的增殖、迁移和侵袭(P<0.05);而过表达Survivin逆转了miR-203对卵巢癌的抑制作用(P<0.05)。结论miR-203通过靶向Survivin抑制EMT从而抑制卵巢癌的增殖、迁移及侵袭,miR-203/Survivin/EMT轴有望成为卵巢癌治疗的新靶点。
Objective To investigate the effects of miR-203 targeting Survivin on the proliferation,migration and invasion of ovarian cancer cells SKOV3 and OVCAR3.Methods After miR-203 over-expressing group,Survivin over-expressing group and black control group of lentiviral vectors were constructed,the SKOV3 and OVCAR3 cells were transfected.After puromycin screening,the blank control group,miR-203 over-expressing group,Survivin over-expressing group,and miR-203 over-expressing plus Survivin group were established.The expressions of Survivin and epithelial-mesenchymal transition(EMT)-related proteins in each group were detected with Western blotting.The proliferation of cells was detected with MTT and plate clone formation assay.The cell migration and invasion were detected with Transwell assay.Results miR-203 over-expression inhibited the expressions of Survivin and EMT(P<0.05).MTT,plate clone formation and Transwell assay illustrated that,compared with the blank control group,the miR-203 over-expressing group had inhibited cell proliferation,migration,and invasion(P<0.05),while the Survivin over-expressing group reversed the inhibitory effects of miR-203(P<0.05).Conclusion miR-203 can inhibit EMT by targeting Survivin to inhibit the proliferation,migration,and invasion of ovarian cancer cells.The miR-203/Survivin/EMT axis is expected to be a new target for the treatment of ovarian cancer.
作者
王宝金
赵欣欣
李霞
马倩
王新月
孙阳
史中娜
WANG Baojin;ZHAO Xinxin;LI Xia;MA Qian;WANG Xinyue;SUN Yang;SHI Zhongna(Department of Gynecology,The Third Affiliated Hospital of Zhengzhou University,Henan International Joint Laboratory of Ovarian Malignancies,Zhengzhou 450052,Henan,China;Department of Gynecology,Fujian Provincial Hospital,Fuzhou 350001,Fujian,China)
出处
《山东大学学报（医学版）》
CAS
北大核心
2020年第12期23-28,37,共7页
Journal of Shandong University:Health Sciences
基金
河南省科技计划项目(192102310067,GHB2019048)。
